nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—SLCO1B3—Methotrexate—multiple sclerosis	0.181	0.366	CbGbCtD
Olmesartan—ABCC2—Dexamethasone—multiple sclerosis	0.115	0.233	CbGbCtD
Olmesartan—SLCO1B1—Methotrexate—multiple sclerosis	0.105	0.213	CbGbCtD
Olmesartan—ABCC2—Methotrexate—multiple sclerosis	0.0926	0.187	CbGbCtD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00328	0.0302	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00328	0.0302	CbGpPWpGaD
Olmesartan—ABCC2—Irinotecan Pathway—BCHE—multiple sclerosis	0.0029	0.0267	CbGpPWpGaD
Olmesartan—SLCO1B1—Irinotecan Pathway—BCHE—multiple sclerosis	0.00272	0.0251	CbGpPWpGaD
Olmesartan—SLCO1B3—Transport of organic anions—ALB—multiple sclerosis	0.00232	0.0213	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—C4A—multiple sclerosis	0.00227	0.0209	CbGpPWpGaD
Olmesartan—AGTR1—Peptide GPCRs—CCR1—multiple sclerosis	0.00195	0.018	CbGpPWpGaD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.00187	0.0172	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL12A—multiple sclerosis	0.00185	0.0171	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CXCL13—multiple sclerosis	0.00185	0.0171	CbGpPWpGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.00175	0.0161	CbGpPWpGaD
Olmesartan—SLCO1B3—Recycling of bile acids and salts—ALB—multiple sclerosis	0.00172	0.0158	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.00169	0.0155	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 trafficking events—ITGA4—multiple sclerosis	0.00168	0.0155	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—FOXP3—multiple sclerosis	0.00159	0.0146	CbGpPWpGaD
Olmesartan—SLCO1B1—Transport of organic anions—ALB—multiple sclerosis	0.00156	0.0143	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-G—multiple sclerosis	0.00144	0.0133	CbGpPWpGaD
Olmesartan—AGTR1—Peptide GPCRs—CXCR3—multiple sclerosis	0.00129	0.0119	CbGpPWpGaD
Olmesartan—AGTR1—Peptide GPCRs—CCR2—multiple sclerosis	0.00126	0.0116	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL17A—multiple sclerosis	0.00125	0.0115	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CD28—multiple sclerosis	0.00122	0.0112	CbGpPWpGaD
Olmesartan—AGTR1—ACE Inhibitor Pathway—TGFB1—multiple sclerosis	0.00119	0.0109	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL12B—multiple sclerosis	0.00116	0.0107	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.00115	0.0106	CbGpPWpGaD
Olmesartan—SLCO1B1—Recycling of bile acids and salts—ALB—multiple sclerosis	0.00115	0.0106	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CD40—multiple sclerosis	0.00111	0.0102	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CTLA4—multiple sclerosis	0.00109	0.0101	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.00107	0.00987	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—GPR65—multiple sclerosis	0.00102	0.00937	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000968	0.00891	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000964	0.00887	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCR1—multiple sclerosis	0.000919	0.00846	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CXCL13—multiple sclerosis	0.000919	0.00846	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—multiple sclerosis	0.00091	0.00838	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.000901	0.0083	CbGpPWpGaD
Olmesartan—SLCO1B3—Bile acid and bile salt metabolism—ALB—multiple sclerosis	0.000897	0.00826	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CD86—multiple sclerosis	0.000868	0.00799	CbGpPWpGaD
Olmesartan—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—multiple sclerosis	0.000859	0.00791	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CD40LG—multiple sclerosis	0.000851	0.00784	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL10—multiple sclerosis	0.000851	0.00784	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.000836	0.00769	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL4—multiple sclerosis	0.000828	0.00762	CbGpPWpGaD
Olmesartan—AGTR1—Peptide GPCRs—CCR5—multiple sclerosis	0.000811	0.00747	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-B—multiple sclerosis	0.00081	0.00745	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.000786	0.00724	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—FAS—multiple sclerosis	0.000763	0.00702	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL2RA—multiple sclerosis	0.000759	0.00698	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-A—multiple sclerosis	0.00075	0.00691	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000734	0.00675	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.000719	0.00662	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—HLA-DRB1—multiple sclerosis	0.000685	0.00631	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.000674	0.0062	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.000655	0.00603	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.00065	0.00599	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—S1PR1—multiple sclerosis	0.000636	0.00586	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—CD80—multiple sclerosis	0.000633	0.00583	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.000616	0.00567	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.000616	0.00567	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.000609	0.0056	CbGpPWpGaD
Olmesartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—multiple sclerosis	0.000603	0.00555	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.000592	0.00545	CbGpPWpGaD
Olmesartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—multiple sclerosis	0.000577	0.00532	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—GPR65—multiple sclerosis	0.000513	0.00472	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000513	0.00472	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IFNG—multiple sclerosis	0.000501	0.00461	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000493	0.00454	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000493	0.00454	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.000492	0.00453	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000492	0.00453	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK1—multiple sclerosis	0.000491	0.00452	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000481	0.00443	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000481	0.00443	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000476	0.00439	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CXCL13—multiple sclerosis	0.000469	0.00432	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CCR1—multiple sclerosis	0.000469	0.00432	CbGpPWpGaD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—multiple sclerosis	0.000467	0.0043	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000463	0.00427	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL1B—multiple sclerosis	0.000446	0.00411	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—IL2—multiple sclerosis	0.000445	0.00409	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000439	0.00404	CbGpPWpGaD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000428	0.00394	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.000423	0.0039	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000423	0.00389	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000408	0.00376	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000397	0.00366	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.000381	0.00351	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000373	0.00343	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000366	0.00337	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—S1PR1—multiple sclerosis	0.00036	0.00331	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000352	0.00324	CbGpPWpGaD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000349	0.00088	CcSEcCtD
Olmesartan—Dermatitis—Azathioprine—multiple sclerosis	0.000349	0.000879	CcSEcCtD
Olmesartan—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000349	0.000878	CcSEcCtD
Olmesartan—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000349	0.000878	CcSEcCtD
Olmesartan—Discomfort—Triamcinolone—multiple sclerosis	0.000348	0.000877	CcSEcCtD
Olmesartan—Discomfort—Methylprednisolone—multiple sclerosis	0.000347	0.000875	CcSEcCtD
Olmesartan—Headache—Azathioprine—multiple sclerosis	0.000347	0.000874	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—TGFB1—multiple sclerosis	0.000347	0.00319	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000344	0.00317	CbGpPWpGaD
Olmesartan—Renal failure—Methotrexate—multiple sclerosis	0.000344	0.000866	CcSEcCtD
Olmesartan—Angioedema—Betamethasone—multiple sclerosis	0.000343	0.000865	CcSEcCtD
Olmesartan—Angioedema—Dexamethasone—multiple sclerosis	0.000343	0.000865	CcSEcCtD
Olmesartan—Angiopathy—Prednisone—multiple sclerosis	0.000341	0.000859	CcSEcCtD
Olmesartan—Malaise—Dexamethasone—multiple sclerosis	0.000339	0.000853	CcSEcCtD
Olmesartan—Malaise—Betamethasone—multiple sclerosis	0.000339	0.000853	CcSEcCtD
Olmesartan—Oedema—Triamcinolone—multiple sclerosis	0.000338	0.000851	CcSEcCtD
Olmesartan—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000338	0.000851	CcSEcCtD
Olmesartan—Vertigo—Betamethasone—multiple sclerosis	0.000338	0.00085	CcSEcCtD
Olmesartan—Vertigo—Dexamethasone—multiple sclerosis	0.000338	0.00085	CcSEcCtD
Olmesartan—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000337	0.000849	CcSEcCtD
Olmesartan—Syncope—Dexamethasone—multiple sclerosis	0.000337	0.000849	CcSEcCtD
Olmesartan—Syncope—Betamethasone—multiple sclerosis	0.000337	0.000849	CcSEcCtD
Olmesartan—Arrhythmia—Prednisone—multiple sclerosis	0.000336	0.000846	CcSEcCtD
Olmesartan—Infection—Triamcinolone—multiple sclerosis	0.000336	0.000846	CcSEcCtD
Olmesartan—Infection—Methylprednisolone—multiple sclerosis	0.000335	0.000844	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CCL3—multiple sclerosis	0.000334	0.00308	CbGpPWpGaD
Olmesartan—Haematuria—Methotrexate—multiple sclerosis	0.000334	0.00084	CcSEcCtD
Olmesartan—Shock—Triamcinolone—multiple sclerosis	0.000332	0.000838	CcSEcCtD
Olmesartan—Insomnia—Prednisolone—multiple sclerosis	0.000332	0.000837	CcSEcCtD
Olmesartan—Alopecia—Prednisone—multiple sclerosis	0.000332	0.000837	CcSEcCtD
Olmesartan—Shock—Methylprednisolone—multiple sclerosis	0.000332	0.000836	CcSEcCtD
Olmesartan—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000331	0.000833	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.00033	0.00304	CbGpPWpGaD
Olmesartan—Loss of consciousness—Betamethasone—multiple sclerosis	0.00033	0.000832	CcSEcCtD
Olmesartan—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00033	0.000832	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.00033	0.00304	CbGpPWpGaD
Olmesartan—Tachycardia—Triamcinolone—multiple sclerosis	0.00033	0.000831	CcSEcCtD
Olmesartan—Mental disorder—Prednisone—multiple sclerosis	0.000329	0.000829	CcSEcCtD
Olmesartan—Nausea—Azathioprine—multiple sclerosis	0.000329	0.000829	CcSEcCtD
Olmesartan—Tachycardia—Methylprednisolone—multiple sclerosis	0.000329	0.000829	CcSEcCtD
Olmesartan—Skin disorder—Methylprednisolone—multiple sclerosis	0.000327	0.000825	CcSEcCtD
Olmesartan—Malnutrition—Prednisone—multiple sclerosis	0.000327	0.000824	CcSEcCtD
Olmesartan—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000327	0.000823	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—S1PR1—multiple sclerosis	0.000327	0.00301	CbGpPWpGaD
Olmesartan—Agranulocytosis—Methotrexate—multiple sclerosis	0.000327	0.000823	CcSEcCtD
Olmesartan—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000326	0.000821	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—TNF—multiple sclerosis	0.000324	0.00298	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000323	0.00297	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000323	0.00297	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—PTGER4—multiple sclerosis	0.000322	0.00296	CbGpPWpGaD
Olmesartan—Asthenia—Mitoxantrone—multiple sclerosis	0.000321	0.00081	CcSEcCtD
Olmesartan—Myalgia—Betamethasone—multiple sclerosis	0.00032	0.000806	CcSEcCtD
Olmesartan—Myalgia—Dexamethasone—multiple sclerosis	0.00032	0.000806	CcSEcCtD
Olmesartan—Anxiety—Dexamethasone—multiple sclerosis	0.000319	0.000803	CcSEcCtD
Olmesartan—Anxiety—Betamethasone—multiple sclerosis	0.000319	0.000803	CcSEcCtD
Olmesartan—Discomfort—Betamethasone—multiple sclerosis	0.000316	0.000796	CcSEcCtD
Olmesartan—Discomfort—Dexamethasone—multiple sclerosis	0.000316	0.000796	CcSEcCtD
Olmesartan—Hypotension—Methylprednisolone—multiple sclerosis	0.000315	0.000794	CcSEcCtD
Olmesartan—Pain—Prednisolone—multiple sclerosis	0.000314	0.000792	CcSEcCtD
Olmesartan—Pharyngitis—Methotrexate—multiple sclerosis	0.000312	0.000785	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CXCR3—multiple sclerosis	0.000311	0.00286	CbGpPWpGaD
Olmesartan—Urinary tract disorder—Methotrexate—multiple sclerosis	0.00031	0.000781	CcSEcCtD
Olmesartan—Vision blurred—Prednisone—multiple sclerosis	0.000308	0.000777	CcSEcCtD
Olmesartan—Urethral disorder—Methotrexate—multiple sclerosis	0.000308	0.000776	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000308	0.000776	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000307	0.000774	CcSEcCtD
Olmesartan—Oedema—Dexamethasone—multiple sclerosis	0.000307	0.000772	CcSEcCtD
Olmesartan—Oedema—Betamethasone—multiple sclerosis	0.000307	0.000772	CcSEcCtD
Olmesartan—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000307	0.000772	CcSEcCtD
Olmesartan—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000307	0.000772	CcSEcCtD
Olmesartan—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000306	0.000772	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—RGS1—multiple sclerosis	0.000306	0.00282	CbGpPWpGaD
Olmesartan—Insomnia—Triamcinolone—multiple sclerosis	0.000306	0.00077	CcSEcCtD
Olmesartan—Insomnia—Methylprednisolone—multiple sclerosis	0.000305	0.000768	CcSEcCtD
Olmesartan—Infection—Betamethasone—multiple sclerosis	0.000305	0.000767	CcSEcCtD
Olmesartan—Infection—Dexamethasone—multiple sclerosis	0.000305	0.000767	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—SRM—multiple sclerosis	0.000304	0.0028	CbGpPWpGaD
Olmesartan—Ill-defined disorder—Prednisone—multiple sclerosis	0.000304	0.000765	CcSEcCtD
Olmesartan—Feeling abnormal—Prednisolone—multiple sclerosis	0.000303	0.000763	CcSEcCtD
Olmesartan—Anaemia—Prednisone—multiple sclerosis	0.000302	0.000762	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CCR2—multiple sclerosis	0.000302	0.00278	CbGpPWpGaD
Olmesartan—Shock—Dexamethasone—multiple sclerosis	0.000302	0.00076	CcSEcCtD
Olmesartan—Shock—Betamethasone—multiple sclerosis	0.000302	0.00076	CcSEcCtD
Olmesartan—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000301	0.000757	CcSEcCtD
Olmesartan—Nervous system disorder—Betamethasone—multiple sclerosis	0.000301	0.000757	CcSEcCtD
Olmesartan—Agitation—Prednisone—multiple sclerosis	0.000301	0.000757	CcSEcCtD
Olmesartan—Thrombocytopenia—Betamethasone—multiple sclerosis	0.0003	0.000756	CcSEcCtD
Olmesartan—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.0003	0.000756	CcSEcCtD
Olmesartan—Tachycardia—Dexamethasone—multiple sclerosis	0.000299	0.000754	CcSEcCtD
Olmesartan—Tachycardia—Betamethasone—multiple sclerosis	0.000299	0.000754	CcSEcCtD
Olmesartan—Angioedema—Prednisone—multiple sclerosis	0.000299	0.000753	CcSEcCtD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000299	0.00275	CbGpPWpGaD
Olmesartan—AGTR1—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000298	0.00274	CbGpPWpGaD
Olmesartan—Dyspepsia—Triamcinolone—multiple sclerosis	0.000297	0.000749	CcSEcCtD
Olmesartan—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000297	0.000748	CcSEcCtD
Olmesartan—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000296	0.000747	CcSEcCtD
Olmesartan—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000296	0.000747	CcSEcCtD
Olmesartan—Malaise—Prednisone—multiple sclerosis	0.000295	0.000743	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000295	0.00271	CbGpPWpGaD
Olmesartan—Vertigo—Prednisone—multiple sclerosis	0.000294	0.00074	CcSEcCtD
Olmesartan—Syncope—Prednisone—multiple sclerosis	0.000293	0.000739	CcSEcCtD
Olmesartan—Anorexia—Betamethasone—multiple sclerosis	0.000292	0.000736	CcSEcCtD
Olmesartan—Anorexia—Dexamethasone—multiple sclerosis	0.000292	0.000736	CcSEcCtD
Olmesartan—Urticaria—Prednisolone—multiple sclerosis	0.000292	0.000735	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000292	0.00269	CbGpPWpGaD
Olmesartan—Fatigue—Triamcinolone—multiple sclerosis	0.000291	0.000734	CcSEcCtD
Olmesartan—Fatigue—Methylprednisolone—multiple sclerosis	0.000291	0.000732	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—GPR65—multiple sclerosis	0.00029	0.00267	CbGpPWpGaD
Olmesartan—Pain—Triamcinolone—multiple sclerosis	0.000289	0.000728	CcSEcCtD
Olmesartan—Loss of consciousness—Prednisone—multiple sclerosis	0.000288	0.000724	CcSEcCtD
Olmesartan—Hypotension—Betamethasone—multiple sclerosis	0.000286	0.000722	CcSEcCtD
Olmesartan—Hypotension—Dexamethasone—multiple sclerosis	0.000286	0.000722	CcSEcCtD
Olmesartan—Angiopathy—Methotrexate—multiple sclerosis	0.000285	0.000718	CcSEcCtD
Olmesartan—Vomiting—Mitoxantrone—multiple sclerosis	0.000285	0.000717	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000284	0.00261	CbGpPWpGaD
Olmesartan—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000283	0.000713	CcSEcCtD
Olmesartan—Rash—Mitoxantrone—multiple sclerosis	0.000282	0.000711	CcSEcCtD
Olmesartan—Dermatitis—Mitoxantrone—multiple sclerosis	0.000282	0.000711	CcSEcCtD
Olmesartan—Headache—Mitoxantrone—multiple sclerosis	0.000281	0.000707	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000279	0.000704	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000279	0.000704	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CNR1—multiple sclerosis	0.000279	0.00257	CbGpPWpGaD
Olmesartan—Myalgia—Prednisone—multiple sclerosis	0.000279	0.000702	CcSEcCtD
Olmesartan—Arthralgia—Prednisone—multiple sclerosis	0.000279	0.000702	CcSEcCtD
Olmesartan—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000278	0.000701	CcSEcCtD
Olmesartan—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000278	0.0007	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—RGS1—multiple sclerosis	0.000278	0.00256	CbGpPWpGaD
Olmesartan—Anxiety—Prednisone—multiple sclerosis	0.000278	0.000699	CcSEcCtD
Olmesartan—Alopecia—Methotrexate—multiple sclerosis	0.000278	0.000699	CcSEcCtD
Olmesartan—Insomnia—Dexamethasone—multiple sclerosis	0.000277	0.000699	CcSEcCtD
Olmesartan—Insomnia—Betamethasone—multiple sclerosis	0.000277	0.000699	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000277	0.000697	CcSEcCtD
Olmesartan—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000276	0.000695	CcSEcCtD
Olmesartan—Discomfort—Prednisone—multiple sclerosis	0.000275	0.000693	CcSEcCtD
Olmesartan—Mental disorder—Methotrexate—multiple sclerosis	0.000275	0.000693	CcSEcCtD
Olmesartan—Malnutrition—Methotrexate—multiple sclerosis	0.000273	0.000689	CcSEcCtD
Olmesartan—Dyspepsia—Dexamethasone—multiple sclerosis	0.00027	0.00068	CcSEcCtD
Olmesartan—Dyspepsia—Betamethasone—multiple sclerosis	0.00027	0.00068	CcSEcCtD
Olmesartan—Urticaria—Triamcinolone—multiple sclerosis	0.000268	0.000676	CcSEcCtD
Olmesartan—Urticaria—Methylprednisolone—multiple sclerosis	0.000268	0.000675	CcSEcCtD
Olmesartan—Body temperature increased—Triamcinolone—multiple sclerosis	0.000267	0.000673	CcSEcCtD
Olmesartan—Anaphylactic shock—Prednisone—multiple sclerosis	0.000267	0.000673	CcSEcCtD
Olmesartan—Oedema—Prednisone—multiple sclerosis	0.000267	0.000673	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000267	0.00245	CbGpPWpGaD
Olmesartan—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000267	0.000671	CcSEcCtD
Olmesartan—Decreased appetite—Dexamethasone—multiple sclerosis	0.000267	0.000671	CcSEcCtD
Olmesartan—Decreased appetite—Betamethasone—multiple sclerosis	0.000267	0.000671	CcSEcCtD
Olmesartan—Nausea—Mitoxantrone—multiple sclerosis	0.000266	0.00067	CcSEcCtD
Olmesartan—Infection—Prednisone—multiple sclerosis	0.000265	0.000668	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000265	0.00244	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000265	0.00244	CbGpPWpGaD
Olmesartan—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000265	0.000667	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000265	0.000667	CcSEcCtD
Olmesartan—Back pain—Methotrexate—multiple sclerosis	0.000264	0.000666	CcSEcCtD
Olmesartan—Fatigue—Dexamethasone—multiple sclerosis	0.000264	0.000666	CcSEcCtD
Olmesartan—Fatigue—Betamethasone—multiple sclerosis	0.000264	0.000666	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—GPR65—multiple sclerosis	0.000263	0.00242	CbGpPWpGaD
Olmesartan—Shock—Prednisone—multiple sclerosis	0.000263	0.000662	CcSEcCtD
Olmesartan—Pain—Betamethasone—multiple sclerosis	0.000262	0.000661	CcSEcCtD
Olmesartan—Pain—Dexamethasone—multiple sclerosis	0.000262	0.000661	CcSEcCtD
Olmesartan—Nervous system disorder—Prednisone—multiple sclerosis	0.000262	0.00066	CcSEcCtD
Olmesartan—Tachycardia—Prednisone—multiple sclerosis	0.000261	0.000656	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.00026	0.0024	CbGpPWpGaD
Olmesartan—Skin disorder—Prednisone—multiple sclerosis	0.000259	0.000653	CcSEcCtD
Olmesartan—Hyperhidrosis—Prednisone—multiple sclerosis	0.000258	0.00065	CcSEcCtD
Olmesartan—Vision blurred—Methotrexate—multiple sclerosis	0.000258	0.000649	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000256	0.00236	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—LINGO1—multiple sclerosis	0.000255	0.00234	CbGpPWpGaD
Olmesartan—Anorexia—Prednisone—multiple sclerosis	0.000255	0.000641	CcSEcCtD
Olmesartan—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000254	0.000639	CcSEcCtD
Olmesartan—Anaemia—Methotrexate—multiple sclerosis	0.000253	0.000637	CcSEcCtD
Olmesartan—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000253	0.000636	CcSEcCtD
Olmesartan—Feeling abnormal—Betamethasone—multiple sclerosis	0.000253	0.000636	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000251	0.00231	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000251	0.000632	CcSEcCtD
Olmesartan—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000251	0.000632	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.00025	0.00231	CbGpPWpGaD
Olmesartan—Malaise—Methotrexate—multiple sclerosis	0.000247	0.000621	CcSEcCtD
Olmesartan—Vertigo—Methotrexate—multiple sclerosis	0.000246	0.000619	CcSEcCtD
Olmesartan—Leukopenia—Methotrexate—multiple sclerosis	0.000245	0.000617	CcSEcCtD
Olmesartan—Urticaria—Betamethasone—multiple sclerosis	0.000244	0.000614	CcSEcCtD
Olmesartan—Urticaria—Dexamethasone—multiple sclerosis	0.000244	0.000614	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000243	0.000613	CcSEcCtD
Olmesartan—Dizziness—Prednisolone—multiple sclerosis	0.000243	0.000612	CcSEcCtD
Olmesartan—Asthenia—Triamcinolone—multiple sclerosis	0.000242	0.000611	CcSEcCtD
Olmesartan—Abdominal pain—Betamethasone—multiple sclerosis	0.000242	0.000611	CcSEcCtD
Olmesartan—Abdominal pain—Dexamethasone—multiple sclerosis	0.000242	0.000611	CcSEcCtD
Olmesartan—Body temperature increased—Betamethasone—multiple sclerosis	0.000242	0.000611	CcSEcCtD
Olmesartan—Body temperature increased—Dexamethasone—multiple sclerosis	0.000242	0.000611	CcSEcCtD
Olmesartan—Asthenia—Methylprednisolone—multiple sclerosis	0.000242	0.000609	CcSEcCtD
Olmesartan—Insomnia—Prednisone—multiple sclerosis	0.000241	0.000608	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000241	0.00222	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CCR1—multiple sclerosis	0.000241	0.00222	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.00024	0.00221	CbGpPWpGaD
Olmesartan—Pruritus—Triamcinolone—multiple sclerosis	0.000239	0.000602	CcSEcCtD
Olmesartan—Cough—Methotrexate—multiple sclerosis	0.000239	0.000601	CcSEcCtD
Olmesartan—Pruritus—Methylprednisolone—multiple sclerosis	0.000239	0.000601	CcSEcCtD
Olmesartan—Dyspepsia—Prednisone—multiple sclerosis	0.000235	0.000592	CcSEcCtD
Olmesartan—Arthralgia—Methotrexate—multiple sclerosis	0.000233	0.000586	CcSEcCtD
Olmesartan—Chest pain—Methotrexate—multiple sclerosis	0.000233	0.000586	CcSEcCtD
Olmesartan—Myalgia—Methotrexate—multiple sclerosis	0.000233	0.000586	CcSEcCtD
Olmesartan—Decreased appetite—Prednisone—multiple sclerosis	0.000232	0.000585	CcSEcCtD
Olmesartan—Rash—Prednisolone—multiple sclerosis	0.000232	0.000584	CcSEcCtD
Olmesartan—Dermatitis—Prednisolone—multiple sclerosis	0.000231	0.000583	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000231	0.000582	CcSEcCtD
Olmesartan—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000231	0.000581	CcSEcCtD
Olmesartan—Fatigue—Prednisone—multiple sclerosis	0.00023	0.00058	CcSEcCtD
Olmesartan—Headache—Prednisolone—multiple sclerosis	0.00023	0.00058	CcSEcCtD
Olmesartan—Discomfort—Methotrexate—multiple sclerosis	0.00023	0.000579	CcSEcCtD
Olmesartan—Constipation—Prednisone—multiple sclerosis	0.000228	0.000575	CcSEcCtD
Olmesartan—Dizziness—Triamcinolone—multiple sclerosis	0.000223	0.000563	CcSEcCtD
Olmesartan—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000223	0.000562	CcSEcCtD
Olmesartan—Dizziness—Methylprednisolone—multiple sclerosis	0.000223	0.000562	CcSEcCtD
Olmesartan—Infection—Methotrexate—multiple sclerosis	0.000222	0.000558	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—TAGAP—multiple sclerosis	0.000221	0.00203	CbGpPWpGaD
Olmesartan—Feeling abnormal—Prednisone—multiple sclerosis	0.00022	0.000554	CcSEcCtD
Olmesartan—Asthenia—Dexamethasone—multiple sclerosis	0.00022	0.000554	CcSEcCtD
Olmesartan—Asthenia—Betamethasone—multiple sclerosis	0.00022	0.000554	CcSEcCtD
Olmesartan—Nervous system disorder—Methotrexate—multiple sclerosis	0.000219	0.000551	CcSEcCtD
Olmesartan—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000218	0.00055	CcSEcCtD
Olmesartan—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000218	0.00055	CcSEcCtD
Olmesartan—Nausea—Prednisolone—multiple sclerosis	0.000218	0.00055	CcSEcCtD
Olmesartan—Pruritus—Dexamethasone—multiple sclerosis	0.000217	0.000546	CcSEcCtD
Olmesartan—Pruritus—Betamethasone—multiple sclerosis	0.000217	0.000546	CcSEcCtD
Olmesartan—Skin disorder—Methotrexate—multiple sclerosis	0.000217	0.000546	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CCL5—multiple sclerosis	0.000216	0.00199	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000216	0.000543	CcSEcCtD
Olmesartan—Vomiting—Triamcinolone—multiple sclerosis	0.000215	0.000541	CcSEcCtD
Olmesartan—Vomiting—Methylprednisolone—multiple sclerosis	0.000214	0.00054	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—CYP27B1—multiple sclerosis	0.000214	0.00197	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP24A1—multiple sclerosis	0.000214	0.00197	CbGpPWpGaD
Olmesartan—Rash—Triamcinolone—multiple sclerosis	0.000213	0.000537	CcSEcCtD
Olmesartan—Dermatitis—Triamcinolone—multiple sclerosis	0.000213	0.000536	CcSEcCtD
Olmesartan—Anorexia—Methotrexate—multiple sclerosis	0.000213	0.000536	CcSEcCtD
Olmesartan—Rash—Methylprednisolone—multiple sclerosis	0.000213	0.000536	CcSEcCtD
Olmesartan—Dermatitis—Methylprednisolone—multiple sclerosis	0.000212	0.000535	CcSEcCtD
Olmesartan—Urticaria—Prednisone—multiple sclerosis	0.000212	0.000534	CcSEcCtD
Olmesartan—Headache—Triamcinolone—multiple sclerosis	0.000212	0.000533	CcSEcCtD
Olmesartan—Headache—Methylprednisolone—multiple sclerosis	0.000211	0.000532	CcSEcCtD
Olmesartan—Abdominal pain—Prednisone—multiple sclerosis	0.000211	0.000532	CcSEcCtD
Olmesartan—Body temperature increased—Prednisone—multiple sclerosis	0.000211	0.000532	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000211	0.00194	CbGpPWpGaD
Olmesartan—Diarrhoea—Betamethasone—multiple sclerosis	0.00021	0.000528	CcSEcCtD
Olmesartan—Diarrhoea—Dexamethasone—multiple sclerosis	0.00021	0.000528	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000209	0.00193	CbGpPWpGaD
Olmesartan—Hypotension—Methotrexate—multiple sclerosis	0.000209	0.000525	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—SRM—multiple sclerosis	0.000204	0.00188	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000203	0.000512	CcSEcCtD
Olmesartan—Dizziness—Betamethasone—multiple sclerosis	0.000203	0.000511	CcSEcCtD
Olmesartan—Dizziness—Dexamethasone—multiple sclerosis	0.000203	0.000511	CcSEcCtD
Olmesartan—Insomnia—Methotrexate—multiple sclerosis	0.000202	0.000508	CcSEcCtD
Olmesartan—Nausea—Triamcinolone—multiple sclerosis	0.000201	0.000506	CcSEcCtD
Olmesartan—Nausea—Methylprednisolone—multiple sclerosis	0.0002	0.000505	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.0002	0.00184	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000198	0.00182	CbGpPWpGaD
Olmesartan—Dyspepsia—Methotrexate—multiple sclerosis	0.000196	0.000495	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—GPC5—multiple sclerosis	0.000196	0.0018	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000196	0.0018	CbGpPWpGaD
Olmesartan—Vomiting—Betamethasone—multiple sclerosis	0.000195	0.000491	CcSEcCtD
Olmesartan—Vomiting—Dexamethasone—multiple sclerosis	0.000195	0.000491	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CCR5—multiple sclerosis	0.000195	0.00179	CbGpPWpGaD
Olmesartan—Decreased appetite—Methotrexate—multiple sclerosis	0.000194	0.000489	CcSEcCtD
Olmesartan—Rash—Dexamethasone—multiple sclerosis	0.000193	0.000487	CcSEcCtD
Olmesartan—Rash—Betamethasone—multiple sclerosis	0.000193	0.000487	CcSEcCtD
Olmesartan—Dermatitis—Dexamethasone—multiple sclerosis	0.000193	0.000487	CcSEcCtD
Olmesartan—Dermatitis—Betamethasone—multiple sclerosis	0.000193	0.000487	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—S1PR1—multiple sclerosis	0.000193	0.00178	CbGpPWpGaD
Olmesartan—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000193	0.000485	CcSEcCtD
Olmesartan—Fatigue—Methotrexate—multiple sclerosis	0.000192	0.000485	CcSEcCtD
Olmesartan—Headache—Dexamethasone—multiple sclerosis	0.000192	0.000484	CcSEcCtD
Olmesartan—Headache—Betamethasone—multiple sclerosis	0.000192	0.000484	CcSEcCtD
Olmesartan—Asthenia—Prednisone—multiple sclerosis	0.000192	0.000483	CcSEcCtD
Olmesartan—Pain—Methotrexate—multiple sclerosis	0.000191	0.000481	CcSEcCtD
Olmesartan—Pruritus—Prednisone—multiple sclerosis	0.000189	0.000476	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—GPC5—multiple sclerosis	0.000188	0.00173	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000186	0.00172	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000185	0.0017	CbGpPWpGaD
Olmesartan—Feeling abnormal—Methotrexate—multiple sclerosis	0.000184	0.000463	CcSEcCtD
Olmesartan—Diarrhoea—Prednisone—multiple sclerosis	0.000183	0.00046	CcSEcCtD
Olmesartan—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000182	0.00046	CcSEcCtD
Olmesartan—Nausea—Betamethasone—multiple sclerosis	0.000182	0.000459	CcSEcCtD
Olmesartan—Nausea—Dexamethasone—multiple sclerosis	0.000182	0.000459	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000182	0.00167	CbGpPWpGaD
Olmesartan—Urticaria—Methotrexate—multiple sclerosis	0.000177	0.000447	CcSEcCtD
Olmesartan—Dizziness—Prednisone—multiple sclerosis	0.000177	0.000445	CcSEcCtD
Olmesartan—Body temperature increased—Methotrexate—multiple sclerosis	0.000176	0.000444	CcSEcCtD
Olmesartan—Abdominal pain—Methotrexate—multiple sclerosis	0.000176	0.000444	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000176	0.00162	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000175	0.00161	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CCL3—multiple sclerosis	0.000172	0.00158	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000171	0.00157	CbGpPWpGaD
Olmesartan—Vomiting—Prednisone—multiple sclerosis	0.00017	0.000428	CcSEcCtD
Olmesartan—Rash—Prednisone—multiple sclerosis	0.000168	0.000424	CcSEcCtD
Olmesartan—Dermatitis—Prednisone—multiple sclerosis	0.000168	0.000424	CcSEcCtD
Olmesartan—Headache—Prednisone—multiple sclerosis	0.000167	0.000421	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000165	0.00152	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RGS1—multiple sclerosis	0.000164	0.00151	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—RRM1—multiple sclerosis	0.000162	0.00149	CbGpPWpGaD
Olmesartan—Asthenia—Methotrexate—multiple sclerosis	0.00016	0.000403	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—CXCR3—multiple sclerosis	0.00016	0.00147	CbGpPWpGaD
Olmesartan—Valsartan—ALB—multiple sclerosis	0.000159	0.672	CrCbGaD
Olmesartan—Nausea—Prednisone—multiple sclerosis	0.000159	0.0004	CcSEcCtD
Olmesartan—Pruritus—Methotrexate—multiple sclerosis	0.000158	0.000398	CcSEcCtD
Olmesartan—AGTR1—GPCR downstream signaling—CNR1—multiple sclerosis	0.000158	0.00145	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GPR65—multiple sclerosis	0.000156	0.00143	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CCR2—multiple sclerosis	0.000155	0.00143	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000153	0.00141	CbGpPWpGaD
Olmesartan—Diarrhoea—Methotrexate—multiple sclerosis	0.000153	0.000385	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—POMC—multiple sclerosis	0.000152	0.0014	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—CCL2—multiple sclerosis	0.000149	0.00137	CbGpPWpGaD
Olmesartan—Dizziness—Methotrexate—multiple sclerosis	0.000148	0.000372	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism—CYP24A1—multiple sclerosis	0.000144	0.00132	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP27B1—multiple sclerosis	0.000144	0.00132	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CNR1—multiple sclerosis	0.000143	0.00132	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCR1—multiple sclerosis	0.000142	0.00131	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CXCL13—multiple sclerosis	0.000142	0.00131	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000142	0.00131	CbGpPWpGaD
Olmesartan—Vomiting—Methotrexate—multiple sclerosis	0.000142	0.000357	CcSEcCtD
Olmesartan—Rash—Methotrexate—multiple sclerosis	0.000141	0.000354	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000141	0.00129	CbGpPWpGaD
Olmesartan—Dermatitis—Methotrexate—multiple sclerosis	0.000141	0.000354	CcSEcCtD
Olmesartan—Headache—Methotrexate—multiple sclerosis	0.00014	0.000352	CcSEcCtD
Olmesartan—Nausea—Methotrexate—multiple sclerosis	0.000133	0.000334	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—TGFB1—multiple sclerosis	0.000132	0.00122	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GPC5—multiple sclerosis	0.000132	0.00121	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CXCL10—multiple sclerosis	0.000129	0.00119	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000126	0.00116	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	0.000124	0.00114	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CCL5—multiple sclerosis	0.000122	0.00113	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000117	0.00108	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CCL5—multiple sclerosis	0.000111	0.00102	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CCR5—multiple sclerosis	0.00011	0.00101	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—RRM1—multiple sclerosis	0.000109	0.001	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000109	0.000999	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000108	0.000996	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCL3—multiple sclerosis	0.000101	0.000933	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CCR5—multiple sclerosis	0.0001	0.000921	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.86e-05	0.000908	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL2RA—multiple sclerosis	9.85e-05	0.000907	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PTGER4—multiple sclerosis	9.76e-05	0.000898	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PGR—multiple sclerosis	9.61e-05	0.000885	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CXCR3—multiple sclerosis	9.42e-05	0.000867	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.38e-05	0.000863	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CD28—multiple sclerosis	9.33e-05	0.000859	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—BCHE—multiple sclerosis	9.32e-05	0.000858	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCR2—multiple sclerosis	9.17e-05	0.000844	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—POMC—multiple sclerosis	8.61e-05	0.000792	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.46e-05	0.000779	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CNR1—multiple sclerosis	8.46e-05	0.000779	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—POMC—multiple sclerosis	7.81e-05	0.000719	CbGpPWpGaD
Olmesartan—Losartan—ALB—multiple sclerosis	7.79e-05	0.328	CrCbGaD
Olmesartan—AGTR1—Signaling by GPCR—CCL2—multiple sclerosis	7.65e-05	0.000704	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CXCL10—multiple sclerosis	7.62e-05	0.000701	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.27e-05	0.000669	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—TYK2—multiple sclerosis	6.94e-05	0.000639	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ALB—multiple sclerosis	6.71e-05	0.000618	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CD86—multiple sclerosis	6.66e-05	0.000613	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.63e-05	0.00061	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCL5—multiple sclerosis	6.56e-05	0.000604	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—IL2—multiple sclerosis	6.36e-05	0.000586	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ALB—multiple sclerosis	6.3e-05	0.00058	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—BCHE—multiple sclerosis	6.26e-05	0.000577	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SPP1—multiple sclerosis	6.07e-05	0.000559	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCR5—multiple sclerosis	5.91e-05	0.000544	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL2RA—multiple sclerosis	5.82e-05	0.000536	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL2—multiple sclerosis	5.78e-05	0.000532	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—APOE—multiple sclerosis	5.61e-05	0.000516	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—APOE—multiple sclerosis	5.37e-05	0.000495	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CD80—multiple sclerosis	4.86e-05	0.000447	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—POMC—multiple sclerosis	4.82e-05	0.000443	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—POMC—multiple sclerosis	4.62e-05	0.000425	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCL2—multiple sclerosis	4.52e-05	0.000416	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—MAPK1—multiple sclerosis	4.42e-05	0.000407	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALB—multiple sclerosis	4.39e-05	0.000404	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TYK2—multiple sclerosis	4.1e-05	0.000378	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—APOE—multiple sclerosis	3.77e-05	0.000347	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL2—multiple sclerosis	3.41e-05	0.000314	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6—multiple sclerosis	3.4e-05	0.000313	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—POMC—multiple sclerosis	3.24e-05	0.000298	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MMP9—multiple sclerosis	3.23e-05	0.000297	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALB—multiple sclerosis	2.95e-05	0.000272	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—STAT3—multiple sclerosis	2.87e-05	0.000264	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MYC—multiple sclerosis	2.67e-05	0.000246	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TGFB1—multiple sclerosis	2.66e-05	0.000245	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MAPK1—multiple sclerosis	2.61e-05	0.00024	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6—multiple sclerosis	2.01e-05	0.000185	CbGpPWpGaD
